ArticleNeurology and therapy2026
Triple Preventive Therapy with OnabotulinumtoxinA, Fremanezumab, and Atogepant in Treatment-Resistant Chronic Migraine: A 52-Week Pilot Case Series (TRIPLE Cohort).
Article in Neurology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionA substantial proportion of patients with chronic migraine (CM) experience persistent disability despite advanced preventive monotherapies, including onabotulinumtoxinA (BoNT-A) and calcitonin gene-related peptide (CGRP)-targeted drugs. Evidence supporting combination strategies remains limited. We evaluated the long-term effectiveness and safety of triple preventive therapy with BoNT-A, fremanezumab, and atogepant in a real-world CM population with refractory disease.
methodsThis ambispective, single-center case series included 14 adults with refractory CM treated sequentially with BoNT-A, fremanezumab, and add-on atogepant (60 mg daily). Patients were followed prospectively for 52 weeks during triple therapy. Primary outcomes were changes in monthly migraine days (MMDs) and monthly headache days (MHDs) through week 52. Secondary outcomes included acute medication use, responder rates, patient-reported outcomes, working status and descriptively reported adverse events and blood-pressure changes. The Patient Global Impression of Change (PGIC) evaluated overall patient-perceived clinical improvement.
resultsDuring triple therapy, MHDs declined from 24.4 ± 2.9 at baseline (stable BoNT-A plus fremanezumab treatment) to 19.0 ± 9.4 at week 52 (overall p = 0.029), with post hoc significance reached only at week 52 (p = 0.020), indicating a delayed treatment effect to reach statistical significance. MMDs decreased progressively to 9.6 ± 5.3 at week 52 (p < 0.001). The ≥ 50% responder rate increased from 28.6% at week 24 to 42.9% at week 52. Acute medication days declined from 12.1 ± 2.4 at baseline to 6.9 ± 2.7 at week 52 (p < 0.001). PGIC scores were 6.5 ± 0.5 at week 52, indicating moderate-to-marked improvement. Working capacity improved substantially, with full-time activity increasing from 21.4% (3/14) at baseline to 71.4% (10/14) at week 52. No serious adverse events or treatment discontinuations were observed in this small cohort.
conclusionIn selected patients with treatment-resistant CM, triple preventive therapy was associated with delayed but clinically meaningful reductions in migraine burden and disability. No major tolerability issues were observed, although the small sample size precludes conclusions regarding safety. These findings support further evaluation of combination strategies in controlled studies.
Indexed as
Identifiers
42839214What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.